^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ivicentamab (GEN-3009)
i
Other names: GEN-3009, GEN3009, DuoHexabody-CD37, ABBV-GMAB-3009
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Genmab
Drug class:
CD37 inhibitor
Related drugs:
over1year
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
P1/2, N=46, Terminated, Genmab | N=182 --> 46 | Trial completion date: Sep 2025 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Sep 2023 --> Nov 2022; Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on any safety or regulatory concerns.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
|
Epkinly (epcoritamab-bysp) • ivicentamab (GEN-3009)
over2years
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
P1/2, N=182, Recruiting, Genmab | Trial completion date: Apr 2025 --> Sep 2025 | Trial primary completion date: Dec 2023 --> Sep 2023
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
|
Epkinly (epcoritamab-bysp) • ivicentamab (GEN-3009)
almost3years
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
P1/2, N=182, Recruiting, Genmab | N=120 --> 182 | Trial completion date: May 2023 --> Apr 2025 | Trial primary completion date: Nov 2022 --> Dec 2023
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
|
Epkinly (epcoritamab-bysp) • ivicentamab (GEN-3009)
Share via
